Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.93 |
| ▸ | EYA2 | O00167 | 1/20 | 0.93 |
| ▸ | APP | P05067 | 1/20 | 0.93 |
| ▸ | ACE | P12821 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 2/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.88 |
| ▸ | TSHR | P16473 | 2/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
| ▸ | DRD1 | P21728 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.88 |
| ▸ | DRD3 | P35462 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL43566 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL5514144 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL905 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8350628 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL5325092 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL705313 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL33500 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL17386368 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL7698156 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL42426 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311934-A1 | HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2016-10-27 | — | — | US | disclosed |
| EP-2976366-A1 | HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS | Fresenius Kabi Deutschland GmbH (DE) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014147175-A1 | HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| EP-2649033-A2 | COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONE COMPOUNDS | Sytheon Ltd. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078546-A2 | COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONE COMPOUNDS | SYTHEON LTD. (US) | 2012-06-14 | — | — | WO | disclosed |
| EP-2296608-A2 | PERSONAL CARE COMPOSITION | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2011-03-23 | — | — | EP | disclosed |
| EP-2296607-A2 | MULTI-PHASE PERSONAL CARE COMPOSITION | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009156248-A2 | PERSONAL CARE COMPOSITION | UNILEVER PLC (GB) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156249-A2 | PERSONAL CARE COMPOSITION | UNILEVER PLC (GB) | 2009-12-30 | — | — | WO | disclosed |
| EP-1993504-A2 | WET WIPES WITH NATURAL ANTIMICROBIAL AGENTS | The Procter & Gamble (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008129494-A1 | ANTIMICROBIAL PRESERVATIVE FREE WIPE | THE PROCTER & GAMBLE COMPANY (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007069214-A2 | WET WIPES WITH NATURAL ANTIMICROBIAL AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-0353188-A2 | Novel expression system | CIBA-GEIGY AG (CH) | 1990-01-31 | — | — | EP | disclosed |
| EP-0278355-A2 | Novel expression system | CIBA-GEIGY AG (CH) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311934-A1 | HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS | MSR1, C3AR1, C1R | TDP1 3151/4885EYA2 2057/4885APP 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.